Form D · Biotechnology

Boston Therapeutics, Inc.

Lawrence, MA · CIK 0001473579

Offering snapshot reported Jul 9, 2021 · SEC filing

Reported sold
$8.43M
Offering amount: $8.43M
Investors reported
Not reported
Form D · investor count
Minimum accepted
Not reported
Reported outside-investor minimum
First sale
Not reported
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jul 9, 2021Initial$8,434,778No comparisonNot reportedSEC filing
Sep 20, 2016Amendment$1,600,000$277,500vs Aug 25, 201628SEC filing
Aug 25, 2016Initial$1,322,500No comparison25SEC filing
Aug 7, 2013Initial$2,000,000No comparison1SEC filing
Jul 5, 2011Initial$508,000No comparison88SEC filing

Offering details

Securities
Not reported
Exemptions
Not reported
Duration over one year
Not reported
Business combination
Not reported
Sales commissions
Not reported
Finders' fees
Not reported
Form D file number
021-405753

Source: Form D, filed Jul 9, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Conroy Chi Heng Cheng Director
Dale H. Conaway Director
Dale Conway Director
Rom Eliaz Director
Henry Esber Director
Alan Hoberman Director
David Ludvigson Director, Executive
Carl Lueders Director
Colin Neill Director
David Platt Director, Executive
David Platt, Ph. D. Director, Executive, Promoter
Carl W. Rausch Executive
Kenneth Tassey, Jr. Director, Executive, Promoter

Issuer details

Industry: Biotechnology (See others in industry)

Address:
354 Merrimack Street #4
Lawrence, MA, 01843